[Reverse remodeling -- paradigm shift in the treatment of pulmonary hypertension].
Ghofrani
H A
HA
Medizinische Klinik II/V, Universitätsklinikum Giessen und Marburg GmbH. ardeschir.ghofrani@innere.med.uni-giessen.de
Schermuly
R T
RT
Weissmann
N
N
Seeger
W
W
Grimminger
F
F
D001549:Benzamides; D002455:Cell Division / Q000187:drug effects; D004359:Drug Therapy, Combination; D019332:Endothelin-1 / Q000037:antagonists & inhibitors; D004730:Endothelium, Vascular / Q000187:drug effects; D005352:Fibromuscular Dysplasia / Q000150:complications / Q000188:drug therapy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000188:drug therapy*; D000068877:Imatinib Mesylate; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage; D010879:Piperazines / Q000008:administration & dosage; D011453:Prostaglandins / Q000008:administration & dosage; D011651:Pulmonary Artery / Q000187:drug effects / Q000503:physiopathology; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy; D011655:Pulmonary Embolism / Q000150:complications / Q000628:therapy; D011743:Pyrimidines / Q000008:administration & dosage; D014665:Vasodilator Agents / Q000008:administration & dosage
D001549:Benzamides; D019332:Endothelin-1; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011453:Prostaglandins; D011743:Pyrimidines; D014665:Vasodilator Agents; D000068877:Imatinib Mesylate